Should a patient with Restless Legs Syndrome who experiences worsening of symptoms each time he starts creatine and improvement when he stops permanently discontinue creatine?

Creatine Should Be Permanently Discontinued in This Patient

Based on the compelling temporal relationship demonstrated through three separate challenge-rechallenge cycles, this patient should permanently discontinue creatine supplementation. While creatine is not listed among the recognized RLS-exacerbating factors in the 2025 American Academy of Sleep Medicine guidelines 1, the patient's consistent symptom pattern represents strong individual evidence of causation.

Understanding the Clinical Evidence

What the Guidelines Tell Us About RLS Exacerbating Factors

The AASM 2025 guidelines identify specific agents known to worsen RLS symptoms, including 2:

• Alcohol consumption
• Caffeine intake
• Antihistaminergic medications (such as diphenhydramine)
• Serotonergic medications (antidepressants like mirtazapine have documented RLS worsening) 3
• Antidopaminergic medications
• Untreated obstructive sleep apnea

Creatine supplementation is notably absent from this comprehensive list, indicating it is not recognized as a standard RLS risk factor 2.

Why This Patient's Case Is Compelling Despite Guideline Silence

The patient has demonstrated a positive rechallenge test three separate times—this represents the gold standard for establishing individual causation in clinical medicine. Each time creatine was started, RLS worsened; each time it was stopped, symptoms improved dramatically. This pattern cannot be dismissed simply because creatine lacks formal recognition in guidelines.

Recommended Management Algorithm

Step 1: Immediate Action

• Permanently discontinue creatine supplementation based on the reproducible temporal relationship
• Document this as a personal RLS-exacerbating factor in the medical record

Step 2: Optimize RLS Management

While discontinuing the offending agent, ensure comprehensive RLS treatment 1, 4:

Check iron parameters and supplement if indicated:

• Measure serum ferritin and transferrin saturation
• If ferritin ≤100 ng/mL or transferrin saturation <20%, initiate iron supplementation 4
• Options include ferrous sulfate 325-650 mg daily/every other day 1 or IV ferric carboxymaltose 1000 mg 1

First-line pharmacologic therapy if needed:

• Gabapentin (strong recommendation, moderate certainty) 1
• Pregabalin (strong recommendation, moderate certainty) 1
• Gabapentin enacarbil 4
• Approximately 70% of patients achieve much or very much improved symptoms with gabapentinoids versus 40% with placebo 4

Step 3: Avoid Dopamine Agonists as First-Line

The AASM now suggests against standard use of dopamine agonists (pramipexole, ropinirole, rotigotine) due to augmentation risk 1:

• Augmentation occurs in 7-10% annually with these agents 4
• Characterized by progressively worsening symptoms, earlier onset, and anatomic spread 5, 6
• These may be reserved for patients who fail gabapentinoids and place higher value on short-term symptom relief 1

Important Clinical Caveats

The Absence of Evidence Is Not Evidence of Absence

While creatine is not formally recognized in RLS guidelines 2, individual patients can have idiosyncratic responses to supplements and medications not captured in population-level studies. The patient's three-time reproducible pattern supersedes the lack of guideline recognition.

Consider Alternative Explanations (But Don't Overthink This Case)

Before attributing symptoms to creatine, one would typically ensure 5, 4:

• No concurrent medication changes (antidepressants, antihistamines)
• No new iron deficiency
• No worsening of comorbid conditions

However, this patient's clear temporal pattern across three separate trials makes alternative explanations highly unlikely.

Document for Future Reference

This case represents valuable clinical information:

• Clearly document creatine as a personal RLS trigger
• Consider reporting to FDA MedWatch or similar pharmacovigilance systems
• This may represent an unrecognized association worthy of further investigation

What About Creatine's Metabolic Effects?

The FDA drug labeling for medications mentions creatine phosphokinase elevations as laboratory findings 7, but these relate to muscle enzyme markers, not creatine supplementation itself. There is no established mechanism linking creatine supplementation to dopaminergic dysfunction or the sensorimotor pathways involved in RLS pathophysiology 8, 9.

Nevertheless, the clinical observation trumps mechanistic uncertainty—if a patient consistently worsens with an agent and improves without it, that agent should be avoided regardless of whether we understand the mechanism.